The update interpretation of 2020 EAU bladder cancer guideline (Part Ⅰ) ——progress of muscle-invasive and metastatic bladder cancer / 中华泌尿外科杂志

ABSTRACT

The 2020 version of the European Association of Urology (EAU) guideline has updated the recommendations for the diagnosis and treatment of muscle-invasive bladder cancer and metastatic bladder cancer. The main changes include ① Pioglitazone use was significantly associated with increased risk of bladder cancer, so pioglitazone should not be prescribed for patients with bladder cancer or a history of bladder cancer. ②Progress involved molecular classification and molecular markers was made but could not be used in routine clinical practice at present. ③ Describes in detail of proper case and technical selection about pelvic organ-sparing radical cystectomy in female patients. ④Low molecular weight haparin usage for 4 weeks can reduce the incidence of postoperative venous thromboembolism. ⑤ PD-L1 positive patients with metastatic bladder cancer ineligible for cisplatin can use pembrolizumab or atezolizumab for first-line immunotherapy.